LIFE aTyr Pharma Inc.

2.92
+0.12  (+4%)
Previous Close 2.8
Open 2.8
Price To Book 0.35
Market Cap 10,301,727
Shares 3,528,593
Volume 82,473
Short Ratio
Av. Daily Volume 121,916

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 final data presented October 5, 2017 at the International Annual Congress of the World Muscle Society (WMS).
Resolaris
Early onset facioscapulohumeral muscular dystrophy (FSHD)
Phase 1b/2 data released December 13, 2016 with further update at EASL April 2017.
Resolaris
Limb girdle muscular dystrophy (LGMD) 2B / Adult patients with facioscapulohumeral muscular dystrophy (FSHD)
Phase 1/2 interim data due 4Q 2019 with final data due mid-2020.
ATYR1923
Pulmonary sarcoidosis

Latest News

  1. Edited Transcript of LIFE earnings conference call or presentation 14-Aug-19 9:00pm GMT
  2. aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
  3. aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
  4. Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
  5. aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
  6. aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
  7. aTyr Pharma Announces Reverse Stock Split to Regain NASDAQ Compliance
  8. Edited Transcript of LIFE earnings conference call or presentation 13-May-19 9:00pm GMT
  9. Atyr Pharma: 1Q Earnings Snapshot
  10. aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
  11. aTyr Pharma to Announce First Quarter 2019 Results on May 13th
  12. aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
  13. aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
  14. Edited Transcript of LIFE earnings conference call or presentation 25-Mar-19 9:00pm GMT
  15. aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
  16. Atyr Pharma (LIFE) Upgraded to Buy: Here's Why
  17. aTyr Pharma Announces Fourth Quarter and Full Year 2018 Results and Provides Corporate Update
  18. aTyr Pharma, Inc. to Host Earnings Call
  19. aTyr Pharma Announces Poster Presentation at the 2019 American Association for Cancer Research (AACR) Annual Meeting